Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)

NCT00613106 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis
Rheumatoid Arthritis
Chronic Low Back Pain
Chronic Regional Pain Syndrome
Chronic Soft Tissue Pain

Interventions

DRUG: HZT-501
DRUG: Ibuprofen

Sponsor

Amgen